SK bioscience, a global innovative vaccine and biotech company based in South Korea, has secured a large-scale commercial production facility which will support entry into the global pneumococcal vaccine market.

 

SK bioscience held a mechanical completion ceremony to mark the expansion of its vaccine manufacturing plant, L HOUSE in Andong, South Korea. The expanded facility will serve as a production site for GBP410, a 21-valent pneumococcal conjugate vaccine (PCV21) candidate jointly developed with global pharmaceutical company Sanofi.

 

Sanofi’s key executives from France and the United States, including Thomas Triomphe, Executive Vice President of Vaccines, joined the event to celebrate and reaffirm the companies’ long-standing collaboration.

 

Both companies viewed the facility expansion as a milestone achievement and a tangible outcome of their strategic partnership, far more than just an infrastructure project. With a shared goal of ensuring a successful global launch of GBP410, they committed to accelerating their joint efforts to establish a strong presence in the global pneumococcal vaccine market.

 

With this expansion, SK bioscience has extended the existing L HOUSE building, adding approximately 4,200 m² of new space. The expanded site will serve as the production base for GBP410, with plans to secure US FDA cGMP certification.

 

GBP410, the 21-valent pneumococcal vaccine co-developed with Sanofi, entered global Phase 3 studies in more than 7,700 healthy infants to adolescents from 6 weeks old up to 17 years across Australia, the US, and Korea. It is the first PCV candidate with more than 20 serotypes to enter phase 3 trials in infants and toddlers and is expected to make a significant contribution to reducing cases of invasive pneumococcal disease (IPD), which remains a serious health concern in this age group.